[go: up one dir, main page]

WO2023122280A3 - Compositions et procédés de traitement de défauts cutanés - Google Patents

Compositions et procédés de traitement de défauts cutanés Download PDF

Info

Publication number
WO2023122280A3
WO2023122280A3 PCT/US2022/053824 US2022053824W WO2023122280A3 WO 2023122280 A3 WO2023122280 A3 WO 2023122280A3 US 2022053824 W US2022053824 W US 2022053824W WO 2023122280 A3 WO2023122280 A3 WO 2023122280A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
compositions
treating skin
skin defects
treatment composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2022/053824
Other languages
English (en)
Other versions
WO2023122280A2 (fr
Inventor
Timothy GEISTLINGER
Janine Lin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Perfect Day Inc
Original Assignee
Perfect Day Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Perfect Day Inc filed Critical Perfect Day Inc
Publication of WO2023122280A2 publication Critical patent/WO2023122280A2/fr
Publication of WO2023122280A3 publication Critical patent/WO2023122280A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4717—Plasma globulins, lactoglobulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne de manière générale l'utilisation d'une composition de traitement pour améliorer la santé de la peau. La composition de traitement comprend une protéine de β-lactoglobuline recombinante pour l'administration d'un agent bioactif à la peau. La présente invention concerne en outre des procédés de production de la composition de traitement et de la protéine de β-lactoglobuline recombinante.
PCT/US2022/053824 2021-12-23 2022-12-22 Compositions et procédés de traitement de défauts cutanés Ceased WO2023122280A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163293554P 2021-12-23 2021-12-23
US63/293,554 2021-12-23

Publications (2)

Publication Number Publication Date
WO2023122280A2 WO2023122280A2 (fr) 2023-06-29
WO2023122280A3 true WO2023122280A3 (fr) 2023-10-12

Family

ID=86903675

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2022/053824 Ceased WO2023122280A2 (fr) 2021-12-23 2022-12-22 Compositions et procédés de traitement de défauts cutanés

Country Status (1)

Country Link
WO (1) WO2023122280A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL276823A (en) 2020-08-19 2022-03-01 Re Milk Ltd Casein formulations and their use
EP4545555A1 (fr) * 2023-10-27 2025-04-30 Real Deal Milk S.L. Proteines recombinantes et leur utilisation dans la therapie du cancer
WO2025133003A2 (fr) * 2023-12-19 2025-06-26 21St.Bio A/S Lactoglobuline bêta bovine non animale

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020219596A1 (fr) * 2019-04-22 2020-10-29 Perfect Day, Inc. Protéines de lait de recombinaison et compositions les comprenant
US20210222186A1 (en) * 2017-04-07 2021-07-22 Alpine Roads, Inc. Milk protein production in transgenic plants
WO2021168343A2 (fr) * 2020-02-19 2021-08-26 Perfect Day, Inc. Protéines de lait recombinantes hypoallergéniques et compositions les comprenant
WO2022031941A1 (fr) * 2020-08-05 2022-02-10 Perfect Day, Inc. Protéines de fusion comprenant des protéines de lait et leurs compositions

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210222186A1 (en) * 2017-04-07 2021-07-22 Alpine Roads, Inc. Milk protein production in transgenic plants
WO2020219596A1 (fr) * 2019-04-22 2020-10-29 Perfect Day, Inc. Protéines de lait de recombinaison et compositions les comprenant
WO2021168343A2 (fr) * 2020-02-19 2021-08-26 Perfect Day, Inc. Protéines de lait recombinantes hypoallergéniques et compositions les comprenant
WO2022031941A1 (fr) * 2020-08-05 2022-02-10 Perfect Day, Inc. Protéines de fusion comprenant des protéines de lait et leurs compositions

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KEPPLER JULIA K., HEYSE ANJA, SCHEIDLER EVA, UTTINGER MAXIMILIAN J., FITZNER LAURA, JANDT UWE, HEYN TIMON R., LAUTENBACH VANESSA, : "Towards recombinantly produced milk proteins: Physicochemical and emulsifying properties of engineered whey protein beta-lactoglobulin variants", FOOD HYDROCOLLOIDS, ELSEVIER BV, NL, vol. 110, 1 January 2021 (2021-01-01), NL , pages 106132, XP055971963, ISSN: 0268-005X, DOI: 10.1016/j.foodhyd.2020.106132 *

Also Published As

Publication number Publication date
WO2023122280A2 (fr) 2023-06-29

Similar Documents

Publication Publication Date Title
WO2023122280A3 (fr) Compositions et procédés de traitement de défauts cutanés
MX2025008493A (es) Agentes de union a fibroblastos y uso de estos
PH12022552738A1 (en) Compositions comprising nanoparticles, method of making and uses thereof
MX2023010711A (es) Fenalquilaminas y métodos de preparación y uso de las mismas.
WO2021007341A3 (fr) Compositions biothérapeutiques vivantes et procédés
MX2020005785A (es) Formulaciones inyectables de toxina botulínica y métodos de uso de las mismas que tienen una alta tasa de respuesta y una larga duración del efecto.
WO2008079270A3 (fr) Coadministration d'alpha-foetoprotéine et d'un agent immunomodulateur pour traiter la sclérose en plaques
CR20230177A (es) Compuestos y composiciones como moduladores de señalización tlr
MX2022002437A (es) Metodos para la produccion de arginasa humana recombinante 1 y sus usos.
MX2023011172A (es) Colageno tipo ii recombinante para uso terapeutico.
MX2024014121A (es) Metodos y composiciones para el tratamiento del exceso de glucocorticoides
PH12022551021A1 (en) Sequential anti-cd19 therapy
WO2019195714A8 (fr) Méthodes et compositions de traitement de maladies de la peau à l'aide de micro-organismes recombinants
MX2017002476A (es) Composiciones y metodos para prevenir o tratar enfermedades, condiciones o procesos caracterizados por proliferacion de fibroblasto aberrante y matriz extracelular.
MX2021010008A (es) Composiciones agricolas para uso en el control y/o tratamiento de enfermedades del tejido vascular en plantas.
MX2025008431A (es) Proteinas de fusion fc de il-12
ZA202102412B (en) Rotomeric isomers of 4-alkyl-5-heteroaryl-3h-1,2- dithiole-3-thiones
ZA202204938B (en) Enhancement and stabilisation of proteolytic activity of proteases
MX2023004450A (es) Combinaciones de péptidos bioactivos novedosas y usos de estas.
MX2023006704A (es) Composiciones dsg2 y metodos para el tratamiento de covid-19.
WO2021111426A3 (fr) Formulation d'histatine-1 pour le traitement, la réparation ou la régénération de tissu osseux chez un sujet
MX2025002733A (es) Composiciones farmaceuticas para el tratamiento de la deficiencia de esfingomielinasa acida
MX2022000433A (es) Proteinas de fusion a toxina para el tratamiento de enfermedades relacionadas con infecciones por cmv.
ZA202402553B (en) Substituted s-alaninate derivatives
HRP20070183A2 (en) Use of androgens to reduce the likelihood of acquiring or to treat skin aging

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22912492

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 22912492

Country of ref document: EP

Kind code of ref document: A2